Myeloid cells expressing LILRB2 are abundant in the tumor microenvironment and can both drive cancer progression and hinder immune responses. Thus, targeting LILRB2 offers a potential strategy to boost immune-based cancer therapies, as it counteracts their suppressive effects on pro-inflammatory pathways.

Orum Therapeutics Inc. has entered into a definitive agreement under which Bristol Myers Squibb Co. has acquired Orum’s ORM-6151 program.

Researchers from GI Innovation Inc. have developed GI-108, a novel bispecific fusion protein designed to augment antitumor immunity.

Briacell Therapeutics Corp. has received IND clearance from the FDA to begin clinical studies with Bria-OTS, the first generation of the company’s personalized off-the-shelf cellular immunotherapy for breast cancer.

CSPC Pharmaceutical Group Ltd.’s SYS-6011 has been cleared by China’s National Medical Products Administration (NMPA) to enter clinical trials in China for solid tumors.

Scientists at the University of California San Francisco (UCSF) have designed a group of synthetic molecules that could prevent the rejection of allogeneic cell transplants. Their strategy consisted of activating the immune checkpoints of different populations of immune cells from the cell surface, but avoiding the cytotoxicity of natural killer (NK) cells and macrophages that would destroy the transplanted cells.

Angiex Inc. has received FDA clearance of its IND application for AGX-101, a novel TM4SF1-directed antibody-drug conjugate (ADC) being developed for the treatment of solid cancers.